Characterization of cannabinoid receptor ligands in tissues natively expressing cannabinoid CB2 receptors

British Journal of Pharmacology

Volumn 169, Issue 4, 2013, Pages 887-899

  Marini, Pietro ^a   Cascio, Maria Grazia ^a   King, Angela ^b,d   Pertwee, Roger G ^a   Ross, Ruth A ^a,c  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

^b MERCK RESEARCH LABORATORIES   (United States)

^c UNIVERSITY OF TORONTO   (Canada)

^d IQVIA   (United States)

Author keywords

35S GTP S; cAMP; cannabinoid; CB2 receptors; hCB2 CHO cells; spleen

Indexed keywords

1 (2,3 DICHLOROBENZOYL) 5 METHOXY 2 METHYL 3 (2 MORPHOLINOETHYL)INDOLE; 1 DEOXY 3 (1,1 DIMETHYLBUTYL) DELTA8 TETRAHYDROCANNABINOL; 2 METHYL 3 (1 NAPHTHOYL) 1 PROPYLINDOLE; 2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 3 (2 IODO 5 NITROBENZOYL) 1 (1 METHYL 2 PIPERIDINYLMETHYL)INDOLE; 4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; 5 (4 CHLORO 3 METHYLPHENYL) 1 (4 METHYLBENZYL) N (1,3,3 TRIMETHYLBICYCLO[2.2.1]HEPTAN 2 YL) 3 PYRAZOLECARBOXAMIDE; 6 IODO 3 (4 METHOXYBENZOYL) 2 METHYL 1 (2 MORPHOLINOETHYL)INDOLE; CANNABINOID 2 RECEPTOR; CANNABINOID 2 RECEPTOR LIGAND; CANNABINOID RECEPTOR AFFECTING AGENT; CYCLIC AMP; GUANOSINE 5' O (3 THIOTRIPHOSPHATE); JTE 907; N (1,3 BENZODIOXOL 5 YLMETHYL) 1,2 DIHYDRO 7 METHOXY 2 OXO 8 (PENTYLOXY) 3 QUINOLINECARBOXAMIDE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CELL MEMBRANE; CHO CELL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; GENETIC TRANSFECTION; HUMAN; HUMAN TISSUE; INHIBITION KINETICS; LIGAND BINDING; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; RAT; SPLEEN;

ANALGESICS; ANIMALS; CANNABINOID RECEPTOR AGONISTS; CELL MEMBRANE; CHO CELLS; CRICETULUS; CYCLIC AMP; DRUG INVERSE AGONISM; GUANOSINE 5'-O-(3-THIOTRIPHOSPHATE); HUMANS; LIGANDS; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; RATS; RATS, WISTAR; RECEPTOR, CANNABINOID, CB2; RECOMBINANT PROTEINS; REPRODUCIBILITY OF RESULTS; SPLEEN;

EID: 84878296917     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.12191     Document Type: Article

References (47)

1. Adamczyk P, Miszkiel J, McCreary AC, Filip M, Papp M, Przegaliński E, (2012). The effects of cannabinoid CB1, CB2 and vanilloid TRPV1 receptor antagonists on cocaine addictive behavior in rats. Brain Res 1444: 45-54.
2. Atwood BK, Wager-Miller J, Haskins C, Straiker A, Mackie K, (2012). Functional selectivity in CB(2) cannabinoid receptor signaling and regulation: implications for the therapeutic potential of CB(2) ligands. Mol Pharmacol 81: 250-263.
3. Bell MR, D'Ambra TE, Kumar V, Eissenstat MA, Herrmann JL Jr, Wetzel JR, et al. (1991). Antinociceptive (aminoalkyl)indoles. J Med Chem 34: 1099-1110.
4. Beltramo M, (2009). Cannabinoid type 2 receptor as a target for chronic-pain. Mini Rev Med Chem 9: 11-25. Review.
5. 2) selective ligand AM1241 and its resolved enantiomers. Br J Pharmacol 151: 1061-1070. Erratum in: Br J Pharmacol 2007; 151: 1137.
6. Bolognini D, Cascio MG, Parolaro D, Pertwee RG, (2012). AM630 behaves as a protean ligand at the human cannabinoid CB(2) receptor. Br J Pharmacol 165: 2561-2574.
7. 2 cannabinoid receptor. Biochim Biophys Acta 1576: 255-264.
8. 2 in immune regulation: therapeutic prospects for neuroinflammation. Expert Rev Mol Med 11: e3.
9. Devane WA, Dysarz FA 3rd, Johnson MR, Melvin LS, Howlett AC, (1988). Determination and characterization of a cannabinoid receptor in rat brain. Mol Pharmacol 34: 605-613.
10. Eissenstat MA, Bell MR, D'Ambra TE, Estep KG, Haycock DA, Olefirowicz EM, et al. (1990). Aminoalkylindoles (AAIs): structurally novel cannabinoid-mimetics. NIDA Res Monogr 105: 427-428.
11. Eissenstat MA, Bell MR, D'Ambra TE, Alexander EJ, Daum SJ, Ackerman JH, et al. (1995). Aminoalkylindoles: structure-activity relationships of novel cannabinoid mimetics. J Med Chem 38: 3094-3105.
12. 2 receptor activation inhibits mechanically evoked responses of wide dynamic range dorsal horn neurons in naïve rats and in rat models of inflammatory and neuropathic pain. Eur J Neurosci 20: 2311-2320.
13. Galiègue S, Mary S, Marchand J, Dussossoy D, Carrière D, Carayon P, et al. (1995). Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur J Biochem 232: 54-61.
14. Gareau Y, Dufresne C, Gallant M, Rochette C, Sawyer N, Slipetz DM, et al. (1996). Structure activity relationships of tetrahydrocannabinol analogues on human cannabinoid receptors. Bioorg Med Chem Lett 6: 189-194.
15. Geiger S, Nickl K, Schneider EH, Seifert R, Heilmann J, (2010). Establishment of recombinant cannabinoid receptor assays and characterization of several natural and synthetic ligands. Naunyn Schmiedebergs Arch Pharmacol 382: 177-191.
16. Gérard CM, Mollereau C, Vassart G, Parmentier M, (1991). Molecular cloning of a human cannabinoid receptor which is also expressed in testis. Biochem J 279 (Pt 1): 129-134.
17. Griffin G, Tao Q, Abood ME, (2000). Cloning and pharmacological characterization of the rat CB(2) cannabinoid receptor. J Pharmacol Exp Ther 292: 886-894.
18. 2 receptors: a therapeutic target for the treatment of inflammatory and neuropathic pain. Br J Pharmacol 153: 319-334.
19. Herkenham M, Lynn AB, Little MD, Johnson MR, Melvin LS, de Costa BR, et al. (1990). Cannabinoid receptor localization in brain. Proc Natl Acad Sci U S A 87: 1932-1936.
20. 2 receptors suppresses hyperalgesia evoked by intradermal capsaicin. J Pharmacol Exp Ther 308: 446-453.
21. Howlett AC, (2002). The cannabinoid receptors. Prostaglandins Other Lipid Mediat 68-69: 619-631.
22. 2 cannabinoid receptors by AM1241 inhibits experimental neuropathic pain: pain inhibition by receptors not present in the CNS. Proc Natl Acad Sci U S A 100: 10529-10533.
23. 2 cannabinoid receptor activation produces antinociception by stimulating peripheral release of endogenous opioids. Proc Natl Acad Sci U S A 102: 3093-3098.
24. Iwamura H, Suzuki H, Ueda Y, Kaya T, Inaba T, (2001). In vitro and in vivo pharmacological characterization of JTE-907, a novel selective ligand for cannabinoid CB2 receptor. J Pharmacol Exp Ther 296: 420-425.
25. Kenakin T, (2001). Inverse, protean, and ligand-selective agonism: matters of receptor conformation. FASEB J 15: 598-611. Review.
26. Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG, (2010). NC3Rs Reporting Guidelines Working Group. Br J Pharmacol 160: 1577-1579.
27. Liu QR, Pan CH, Hishimoto A, Li CY, Xi ZX, Llorente-Berzal A, et al. (2009). Species differences in cannabinoid receptor 2 (CNR2 gene): identification of novel human and rodent CB2 isoforms, differential tissue expression and regulation by cannabinoid receptor ligands. Genes Brain Behav 8: 519-530.
28. 2 cannabinoid receptor-mediated peripheral antinociception. Pain 93: 239-245.
29. 2 cannabinoid receptor agonists: pain relief without psychoactive effects? Curr Opin Pharmacol 3: 62-67. Review.
30. Mancini I, Brusa R, Quadrato G, Foglia C, Scandroglio P, Silverman L, et al. (2009). Constitutive activity of cannabinoid-2 (CB2) receptors plays an essential role in the protean agonism of (+)AM1241 and L768242. Br J Pharmacol 158: 382-391.
31. Marriott KS, Huffman JW, (2008). Recent advances in the development of selective ligands for the cannabinoid CB(2) receptor. Curr Top Med Chem 8: 187-204.
32. Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI, (1990). Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346: 561-564.
33. McGrath J, Drummond G, McLachlan E, Kilkenny C, Wainwright C, (2010). Guidelines for reporting experiments involving animals: the ARRIVE guidelines. Br J Pharmacol 160: 1573-1576.
34. Munro S, Thomas KL, Abu-Shaar M, (1993). Molecular characterization of a peripheral receptor for cannabinoids. Nature 365: 61-65.
35. Onaivi ES, Ishiguro H, Gong JP, Patel S, Meozzi PA, Myers L, et al. (2008). Functional expression of brain neuronal CB2 cannabinoid receptors are involved in the effects of drugs of abuse and in depression. Ann N Y Acad Sci 1139: 434-449.
36. Portier M, Rinaldi-Carmona M, Pecceu F, Combes T, Poinot-Chazel C, Calandra B, et al. (1999). SR 144528, an antagonist for the peripheral cannabinoid receptor that behaves as an inverse agonist. J Pharmacol Exp Ther 288: 582-589.
37. Quartilho A, Mata HP, Ibrahim MM, Vanderah TW, Porreca F, Makriyannis A, et al. (2003). Inhibition of inflammatory hyperalgesia by activation of peripheral CB2 cannabinoid receptors. Anesthesiology 99: 955-960.
38. Rayman N, Lam KH, Laman JD, Simons PJ, Löwenberg B, Sonneveld P, et al. (2004). Distinct expression profiles of the peripheral cannabinoid receptor in lymphoid tissues depending on receptor activation status. J Immunol 172: 2111-2117.
39. 2 cannabinoid receptors of L759633, L759656, and AM630. Br J Pharmacol 126: 665-672.
40. Shire D, Calandra B, Rinaldi-Carmona M, Oustric D, Pessègue B, Bonnin-Cabanne O, et al. (1996). Molecular cloning, expression and function of the murine CB2 peripheral cannabinoid receptor. Biochim Biophys Acta 1307: 132-136.
41. Smit MJ, Vischer HF, Bakker RA, (2007). Pharmacogenomic and structural analysis of constitutive G protein-coupled receptor activity. Annu Rev Pharmacol Toxicol 47: 53-87.
42. Sutor S, Heilmann J, Seifert R, (2011). Impact of fusion to Gαi2 and co-expression with RGS proteins on pharmacological properties of human cannabinoid receptors CB1R and CB2R. J Pharm Pharmacol 63: 1043-1055.
43. Thomas A, Stevenson LA, Wease KN, Price MR, Baillie G, Ross RA, Pertwee RG, (2005). Evidence that the plant cannabinoid Delta9-tetrahydrocannabivarin is a cannabinoid CB1 and CB2 receptor antagonist. Br J Pharmacol 146: 917-926.
44. Valenzano KJ, Tafesse L, Lee G, Harrison JE, Boulet JM, Gottshall SL, et al. (2005). Pharmacological and pharmacokinetic characterization of the cannabinoid receptor 2 agonist, GW405833, utilizing rodent models of acute and chronic pain, anxiety, ataxia and catalepsy. Neuropharmacology 48: 658-672.
45. Van Sickle MD, Duncan M, Kingsley PJ, Mouihate A, Urbani P, Mackie K, et al. (2005). Identification and functional characterization of brainstem cannabinoid CB2 receptors. Science 310: 329-332.
46. 2 receptors modulate cocaine's actions in mice. Nat Neurosci 14: 1160-1166.
47. Yao BB, Mukherjee S, Fan Y, Garrison TR, Daza AV, Grayson GK, et al. (2006). In vitro pharmacological characterization of AM1241: a protean agonist at the cannabinoid CB2 receptor? Br J Pharmacol 149: 145-154.